

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 August 2024 (22.08.2024)



(10) International Publication Number
WO 2024/173173 A1

(51) International Patent Classification:

A61P 17/00 (2006.01) *A61P 29/00* (2006.01)
A61K 31/4985 (2006.01) *A61P 37/00* (2006.01)
A61P 19/00 (2006.01) *C07D 487/04* (2006.01)

(21) International Application Number:

PCT/US2024/015156

(22) International Filing Date:

09 February 2024 (09.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/484,684	13 February 2023 (13.02.2023)	US
63/511,519	30 June 2023 (30.06.2023)	US
63/516,399	28 July 2023 (28.07.2023)	US
63/602,304	22 November 2023 (22.11.2023)	US

(71) Applicant: **DICE ALPHA, INC.** [US/US]; c/o Eli Lilly and Company, Lilly Corporate Office, Indianapolis, Indiana 46285 (US).

(72) Inventors: **FATHEREE, Paul R.**; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **REILLY, Maureen K.**; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **BELABED, Hassane**; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **FREIDBERG, Michael D.**; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **BRANDT, Gary Edward Lee**; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agent: **WOOD, Danny L.** et al.; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: IMIDAZOTRIAZINE IL-17A MODULATORS AND USES THEREOF

(57) Abstract: The disclosure herein provides lactam substituted imidazotriazine compounds or salts of Formula (I'), (I), (II), (II-a), (II-b), or (A), and pharmaceutical compositions thereof, for the modulation of IL-17A. These compounds are useful in the treatment of inflammatory conditions such as psoriasis.

WO 2024/173173 A1